WHO: New Oral Treatment More Effective in Combating Multidrug-Resistant TBTuberculosis has plagued humans for thousands of years and continues to do so. In advance of this year’s World TB Day, March 24, the World Health Organization is issuing a call to action to eradicate the disease by 2030. As part of these efforts, the WHO is launching an oral drug regimen it says can more effectively treat people with multi-drug resistant tuberculosis. TB remains the world’s deadliest infectious disease, killing nearly 4,500 people a day and infecting 10 million people a year.\n\nDespite the grim statistics, much progress has been made in the diagnosis, prevention and treatment of the disease. The WHO says 54 million lives have been saved since 2000. But the WHO also warns the gains risk being lost with the emergence of multidrug-resistant TB or MDR-TB.\n\nThe current treatment for MDR-TB involves a two-year treatment course of painful injections, which provoke many bad side effects. \n\nThe WHO says it is hopeful the new oral treatment program it is launching will be more effective in controlling the spread of the particularly virulent form of tuberculosis. \n\nThe director of the WHO’s Global TB Program, Tereza Kasaeva, told VOA the new oral drug treatment the WHO is recommending has far fewer adverse side effects.\n\n“Of course, it will be definitely much, much easier and there will not be a need for regular frequent visits of the physicians or health workers for making these injections. No doubt, as we see from the data, the effectiveness, the treatment success will be definitely much, much higher,” Kasaeva said.\n\nThe South African government has announced it plans to adopt the injection-free treatment. Kasaeva said the cost of the oral treatment is around $2,000, which is largely unaffordable for low-income countries. \n\nShe said South Africa is engaging in talks with pharmaceutical companies to drop the price to $400. The WHO says South Africa is one of the 20 countries most affected by MDR-TB. Others include Russia, China, India, Nigeria, Pakistan and Vietnam.